328 related articles for article (PubMed ID: 23629715)
1. Pharmacokinetics of first-line tuberculosis drugs in Tanzanian patients.
Tostmann A; Mtabho CM; Semvua HH; van den Boogaard J; Kibiki GS; Boeree MJ; Aarnoutse RE
Antimicrob Agents Chemother; 2013 Jul; 57(7):3208-13. PubMed ID: 23629715
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines.
Bekker A; Schaaf HS; Draper HR; van der Laan L; Murray S; Wiesner L; Donald PR; McIlleron HM; Hesseling AC
Antimicrob Agents Chemother; 2016 Apr; 60(4):2171-9. PubMed ID: 26810651
[TBL] [Abstract][Full Text] [Related]
3. Plasma concentrations of isoniazid and rifampin are decreased in adult pulmonary tuberculosis patients with diabetes mellitus.
Babalik A; Ulus IH; Bakirci N; Kuyucu T; Arpag H; Dagyildizi L; Capaner E
Antimicrob Agents Chemother; 2013 Nov; 57(11):5740-2. PubMed ID: 23979746
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of Antituberculosis Drugs in HIV-Positive and HIV-Negative Adults in Malawi.
van Oosterhout JJ; Dzinjalamala FK; Dimba A; Waterhouse D; Davies G; Zijlstra EE; Molyneux ME; Molyneux EM; Ward S
Antimicrob Agents Chemother; 2015 Oct; 59(10):6175-80. PubMed ID: 26248378
[TBL] [Abstract][Full Text] [Related]
5. Effect of diabetes mellitus on TB drug concentrations in Tanzanian patients.
Mtabho CM; Semvua HH; van den Boogaard J; Irongo CF; Boeree MJ; Colbers A; Burger DM; van Crevel R; van der Ven AJAM; Kibiki GS; Tostmann A; Aarnoutse RE
J Antimicrob Chemother; 2019 Dec; 74(12):3537-3545. PubMed ID: 31651031
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of the First-Line Antituberculosis Drugs in Ghanaian Children with Tuberculosis with or without HIV Coinfection.
Antwi S; Yang H; Enimil A; Sarfo AM; Gillani FS; Ansong D; Dompreh A; Orstin A; Opoku T; Bosomtwe D; Wiesner L; Norman J; Peloquin CA; Kwara A
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27855070
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected Indian children.
Mukherjee A; Velpandian T; Singla M; Kanhiya K; Kabra SK; Lodha R
Int J Tuberc Lung Dis; 2016 May; 20(5):666-72. PubMed ID: 27084822
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis.
Chirehwa MT; McIlleron H; Rustomjee R; Mthiyane T; Onyebujoh P; Smith P; Denti P
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607022
[TBL] [Abstract][Full Text] [Related]
9. Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.
Verbeeck RK; Günther G; Kibuule D; Hunter C; Rennie TW
Eur J Clin Pharmacol; 2016 Aug; 72(8):905-16. PubMed ID: 27305904
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients.
Ruslami R; Nijland HM; Alisjahbana B; Parwati I; van Crevel R; Aarnoutse RE
Antimicrob Agents Chemother; 2007 Jul; 51(7):2546-51. PubMed ID: 17452486
[TBL] [Abstract][Full Text] [Related]
11. Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
Chigutsa E; Pasipanodya JG; Visser ME; van Helden PD; Smith PJ; Sirgel FA; Gumbo T; McIlleron H
Antimicrob Agents Chemother; 2015 Jan; 59(1):38-45. PubMed ID: 25313213
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania.
Denti P; Jeremiah K; Chigutsa E; Faurholt-Jepsen D; PrayGod G; Range N; Castel S; Wiesner L; Hagen CM; Christiansen M; Changalucha J; McIlleron H; Friis H; Andersen AB
PLoS One; 2015; 10(10):e0141002. PubMed ID: 26501782
[TBL] [Abstract][Full Text] [Related]
13. Population Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Pregnant South African Women with Tuberculosis and HIV.
Abdelwahab MT; Leisegang R; Dooley KE; Mathad JS; Wiesner L; McIlleron H; Martinson N; Waja Z; Letutu M; Chaisson RE; Denti P
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31844002
[TBL] [Abstract][Full Text] [Related]
14. Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.
Chideya S; Winston CA; Peloquin CA; Bradford WZ; Hopewell PC; Wells CD; Reingold AL; Kenyon TA; Moeti TL; Tappero JW
Clin Infect Dis; 2009 Jun; 48(12):1685-94. PubMed ID: 19432554
[TBL] [Abstract][Full Text] [Related]
15. Rifampicin and Isoniazid Maximal Concentrations are Below Efficacy-associated Thresholds in the Majority of Patients: Time to Increase the Doses?
Trentalange A; Borgogno E; Motta I; Antonucci M; Pirriatore V; Costa C; Rossi G; Barco A; De Nicolò A; Piccioni P; D'Avolio A; Bonora S; Di Perri G; Calcagno A
Int J Antimicrob Agents; 2021 Mar; 57(3):106297. PubMed ID: 33539932
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of anti-tuberculosis drugs in Venezuelan children younger than 16 years of age: supportive evidence for the implementation of revised WHO dosing recommendations.
Verhagen LM; López D; Hermans PW; Warris A; de Groot R; García JF; de Waard JH; Aarnoutse RE
Trop Med Int Health; 2012 Dec; 17(12):1449-56. PubMed ID: 23094704
[TBL] [Abstract][Full Text] [Related]
17. Oral bioavailability of rifampicin, isoniazid, ethambutol, and pyrazinamide in a 4-drug fixed-dose combination compared with the separate formulations in healthy Chinese male volunteers.
Xu J; Jin H; Zhu H; Zheng M; Wang B; Liu C; Chen M; Zhou L; Zhao W; Fu L; Lu Y
Clin Ther; 2013 Feb; 35(2):161-8. PubMed ID: 23410999
[TBL] [Abstract][Full Text] [Related]
18. Cohort profile of a study on outcomes related to tuberculosis and antiretroviral drug concentrations in Uganda: design, methods and patient characteristics of the SOUTH study.
Sekaggya-Wiltshire C; Castelnuovo B; von Braun A; Musaazi J; Muller D; Buzibye A; Gutteck U; Henning L; Ledergerber B; Corti N; Lamorde M; Fehr J; Kambugu A
BMJ Open; 2017 Sep; 7(9):e014679. PubMed ID: 28928173
[TBL] [Abstract][Full Text] [Related]
19. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients.
McIlleron H; Wash P; Burger A; Norman J; Folb PI; Smith P
Antimicrob Agents Chemother; 2006 Apr; 50(4):1170-7. PubMed ID: 16569826
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients.
Rockwood N; Meintjes G; Chirehwa M; Wiesner L; McIlleron H; Wilkinson RJ; Denti P
Antimicrob Agents Chemother; 2016 Oct; 60(10):6050-9. PubMed ID: 27480859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
